2-cycloheptylcycloheptanone | 1027177-22-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-cycloheptylcycloheptanone
• 英文别名: Bicycloheptanone；2-cycloheptylcycloheptan-1-one
• CAS: 1027177-22-5
• 化学式: C₁₄H₂₄O
• 分子量: 208.344
• InChiKey: OGUSLZCCQIWHTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  环庚醇 在 [RuCl₂(p-cymene)(iPr₂-imy)] 、 tricyclohexylphosphine tetrafluoroborate 、 potassium hydroxide 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以70%的产率得到2-cycloheptylcycloheptanone
  参考文献：
  名称：

  Ruthenium-Catalyzed Self-Coupling of Primary and Secondary Alcohols with the Liberation of Dihydrogen

  摘要：

  The dehydrogenative self-condensation of primary and secondary alcohols has been studied in the presence of RuCl2(IiPr)(p-cymene). The conversion of primary alcohols into esters has been further optimized by using magnesium nitride as an additive, which allows the reaction to take place at a temperature and catalyst loading lower than those described previously. Secondary alcohols were dimerized into racemic ketones by a dehydrogenative Guerbet reaction with potassium hydroxide as the additive. The transformation gave good yields of the ketone diners with a range of alkan-2-ols, whereas more substituted secondary alcohols were unreactive. The reaction proceeds by dehydrogenation to the ketone, followed by an aldol reaction and hydrogenation of the resulting enone.

  DOI：

  10.1021/jo4008699

文献信息

• [EN] PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS DE PSILOCINE EN TANT QU'AGENTS SÉROTONINERGIQUES SÉROTONINERGIQUES POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
  申请人：MINDSET PHARMA INC

  公开号：WO2021155470A1

  公开（公告）日：2021-08-12

  The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. (I)

  本申请涉及公式（I）的哌嗪酮衍生物，以及其制备方法、包含它们的组合物以及它们在细胞中激活5-羟色胺受体的使用，以及通过激活细胞中的5-羟色胺受体治疗疾病、障碍或病况。 (I)
• [EN] 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS DE 3-PYRROLIDINE-INDOLE EN TANT QU'AGENTS PSYCHÉDÉLIQUES SÉROTONINERGIQUES POUR LE TRAITEMENT DE TROUBLES DU SNC
  申请人：MINDSET PHARMA INC

  公开号：WO2021155467A1

  公开（公告）日：2021-08-12

  The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions. Formula (I)

  本申请涉及一般式（I）的3-环氨基吲哚衍生物，以及它们的制备方法、包含它们的组合物和它们在细胞中激活5-羟色胺受体以及通过激活细胞中的5-羟色胺受体治疗疾病、障碍或病况的用途。这些疾病、障碍或病况包括精神病、精神疾病和其他神经疾病、障碍和病况。式（I）：
• [EN] 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS D'AMINE-INDOLE 3-CYCLIQUE UTILISÉS EN TANT QU'AGENTS SÉROTONERGIQUES POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
  申请人：MINDSET PHARMA INC

  公开号：WO2022120475A1

  公开（公告）日：2022-06-16

  The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, and treating diseases, disorders or conditions treatable by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis and mental illness. (Formula (I))

  本申请涉及一般式(I)的3-环氨基吲哚衍生物，其制备过程，包含它们的组合物以及它们在细胞中激活5-羟色胺受体和治疗可通过细胞中5-羟色胺受体激活治疗的疾病、失调或病症的用途。这些疾病、失调或病症包括精神病和精神疾病。(式(I))
• Novel (3.2.0.) bicycloheptanone oxime ethers with valuable therapeutic properties
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0100900A1

  公开（公告）日：1984-02-22

  Compounds useful in treating cardiovascular disorders are the carboxylic acids depicted in formulas (1) and (2) as well as their pharmaceutically acceptable, non-toxic salts and esters, wherein: n is an integer from one to four; R1 is hydroxy; R2 is hydrogen; or R1 and Rz together are an oxo group; R3 is wherein A is -CH2-CH2-; trans-CH=CH-; -C≡C-; and R4 is linear or branched alkyl of one to twelve carbons, cycloalkyl of three to eight carbons; phenyl optionally substituted with one or two identical substituents selected from the group consisting of lower alkyl, lower alkoxy, hydroxy, trifluoromethyl, and halo; or optionally substituted phenylalkyl.

  用于治疗心血管疾病的化合物是式(1)和(2)所示的羧酸类化合物 及其药学上可接受的无毒盐类和酯类，其中 n 是一至四的整数； R1 是羟基 R2 是氢；或 R1 和 Rz 合在一起是一个氧代基团； R3 是 其中 A 是-CH2-CH2-；反式-CH=CH-；-C≡C-；和 R4 是 1 至 12 个碳原子的直链或支链烷基、3 至 8 个碳原子的环烷基、任选被选自低 级烷基、低级烷氧基、羟基、三氟甲基和卤基的一个或两个相同取代基取代的苯基、 或任选被取代的苯基烷基。
• Benzoxepin derivatives
  申请人：SUNTORY LIMITED

  公开号：EP0388188A1

  公开（公告）日：1990-09-19

  A benzoxepin derivative represented by the formula(I): wherein R represents a heterocyclyc group, and salts thereof; a process for production thereof comprising the steps of reducing an oxime represented by the formula (V): wherein R has the same meaning as defined in the formula (I), and hydrolyzing the intermediate produced of the above reduction; and pharmaceuticals comprising the compound (I).

  一种由式(I)代表的苯并氧塞平衍生物： 其中 R 代表杂环基团，及其盐类；其生产工艺包括以下步骤：还原由式（V）代表的肟： 式（V）代表的肟，其中 R 的含义与式（I）中定义的相同，以及水解上述还原产生的中间体；以及包含化合物（I）的药物。